Get the Stockscreener App
2.8129
1.30%
-0.0371
Anixa Biosciences Inc stock is traded at $2.8129, with a volume of 6,543.
It is down -1.30% in the last 24 hours and down -4.97% over the past month.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
See More
Previous Close:
$2.85
Open:
$2.84
24h Volume:
6,543
Relative Volume:
0.07
Market Cap:
$88.82M
Revenue:
-
Net Income/Loss:
$-12.48M
P/E Ratio:
-7.2126
EPS:
-0.39
Net Cash Flow:
$-7.93M
1W Performance:
+4.57%
1M Performance:
-4.97%
6M Performance:
-8.08%
1Y Performance:
-11.26%
1-Day Range:
$2.7188
$2.87
1-Week Range:
$2.55
$2.88
52-Week Range:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.76 | 88.82M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.52 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.45 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.14 | 36.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
227.10 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
236.16 | 25.73B | 3.81B | -644.79M | -669.77M | -6.24 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences- Receives Notice Of Allowance For Car-T Technology Patent - MarketScreener
Anixa Biosciences Receives Notice of Allowance from U.S. Patent - GuruFocus
Anixa Biosciences (ANIX) Secures Patent to Advance CAR-T Cancer Therapy | ANIX Stock News - GuruFocus
Major Patent Win: Anixa's Revolutionary CAR-T Cancer Treatment Gains Key Protection - Stock Titan
Anixa Biosciences (NASDAQ:ANIX) Earns “Buy” Rating from D. Boral Capital - Defense World
Anixa Biosciences Stock Price, Quotes and Forecasts - Benzinga
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up - MSN
Anixa gains US patent for breast cancer vaccine technology - Investing.com Australia
Anixa gains US patent for breast cancer vaccine technology By Investing.com - Investing.com Canada
Anixa Biosciences Shares Rise After Notice of Patent Allowance for Breast Cancer Vaccine - MarketScreener
Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology - BioSpace
Anixa Biosciences stock rises on patent win (ANIX:NASDAQ) - Seeking Alpha
Anixa Biosciences Receives Notice Of Allowance From U.S. Patent And Trademark Office - MarketScreener
EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent - Yahoo
EF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th - PR Newswire
Leading Cancer biotech Anixa Biosciences Unveils Latest Innovations at Major Healthcare Conference - Stock Titan
Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral Capital - Defense World
What is HC Wainwright’s Forecast for ANIX Q1 Earnings? - Defense World
Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Anixa Enters Letter of Intent to Develop Verdi's AI-Guided Cancer Vaccines - MarketScreener
Anixa Biosciences Enters Letter of Intent with VERDI Solutions t - GuruFocus
VERDI Grants Anixa 6-month Right To Negotiate Transaction For Development Of VERDI's Cancer Vaccines - Nasdaq
Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines - Marketscreener.com
EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines - Benzinga
Game-Changing AI Cancer Vaccine Shows Early Success: Anixa Secures Exclusive Rights - Stock Titan
Anixa secures US patent for ovarian cancer vaccine tech By Investing.com - Investing.com Australia
EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine - AOL.com
Anixa secures US patent for ovarian cancer vaccine tech - Investing.com India
Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine - Marketscreener.com
Maxim Group Begins Coverage on Anixa Biosciences (NASDAQ:ANIX) - Defense World
Maxim Group Initiates Coverage of Anixa Biosciences (ANIX) with Buy Recommendation - MSN
Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th - Quantisnow
Anixa Biosciences Holds Annual Stockholder Meeting 2025 - TipRanks
This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
Groundbreaking CAR-T and Cancer Vaccine Updates: Anixa CEO to Present Latest Breakthroughs - StockTitan
Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties - BioSpace
Anixa Biosciences Annual Meeting to Feature CEO Update and Investor Q&A - StockTitan
Anixa Biosciences (ANIX) to Release Earnings on Tuesday - Defense World
Anixa Biosciences to Present at the 18th Annual European Life Sc - GuruFocus.com
Anixa Biosciences : to Hold Conference Call to Discuss Outlook for 2019 -January 16, 2019 at 07:31 am EST - MarketScreener
Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th - PR Newswire
How Anixa's Revolutionary Ovarian Cancer Therapy Will Take Center Stage at Major Gene Therapy Summit - Stock Titan
Spotlight On February 2025's Promising Penny Stocks - Yahoo Finance
Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial - PR Newswire
Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox New - GuruFocus
Can This Breast Cancer Vaccine Change Prevention Forever? Anixa's Trial Shows 70% Response Rate - StockTitan
Anixa Biosciences Featured in Breaking Cancer News Article on No - GuruFocus.com
Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer - PR Newswire
Can This Groundbreaking CAR-T Therapy Transform Ovarian Cancer Treatment? - Stock Titan
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anixa Biosciences Inc Stock (ANIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
| Titterton Lewis H jr | Director |
Jan 21 '25 |
Buy |
2.59 |
6,000 |
15,540 |
928,334 |
| Titterton Lewis H jr | Director |
Jan 17 '25 |
Buy |
2.57 |
10,000 |
25,700 |
922,334 |
| KUMAR AMIT | Chief Executive Officer |
Jan 15 '25 |
Buy |
2.23 |
43,000 |
95,890 |
559,925 |
| Catelani Michael | President, COO, & CFO |
Jan 15 '25 |
Buy |
2.15 |
9,289 |
19,971 |
44,500 |
| Titterton Lewis H jr | Director |
Oct 22 '24 |
Option Exercise |
2.58 |
16,000 |
41,200 |
912,334 |
| Titterton Lewis H jr | Director |
Jul 30 '24 |
Buy |
3.06 |
21,646 |
66,237 |
890,754 |
| Titterton Lewis H jr | Director |
Jul 31 '24 |
Buy |
3.23 |
5,580 |
18,023 |
896,334 |
1.19%
2.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):